Evaluation of the clinical efficacy of asenapine in schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 2107-2115

  Minassian, Arpi ^a   Young, Jared W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; Asenapine; Bipolar disorder; Dopamine; SAPHRIS; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BIFEPRUNOX; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT; SEROTONIN ANTAGONIST;

AKATHISIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; HYPESTHESIA; NEGATIVE SYNDROME; ORAL HYPOESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 77954787424     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.506188     Document Type: Review

References (66)

1. Perenyi A, Forlano R. Suicide in schizophrenia. Neuropsychopharmacol Hung 2005;7:107-117
2. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl 7):4-18
3. Taylor DM. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002;159:1062
4. Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008;59:523-525
5. Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009;35:931-936
6. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Pscyh 1996;153:321-330
7. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(Suppl 9):3-8, discussion 36-42
8. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 2005;315:1278-1287
9. Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993;245:179-182
10. Taylor DM, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009;70:196-200
11. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63:1762-1784
12. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/ norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-914
13. Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother 2010;44:863-870
14. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8:539-554
15. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS drugs 2004;18:251-267
16. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology 2008;200:317-331
17. Broekkamp CL, De Graaf JS, van Delft AM. Behavioural pharmacology of trans-5-chloro-2- methyl-2,3,3a,12b-tetrahydro- 1H-dibenz [2,3:6,7]oxepino-[4,5- c]pyrrolidine male- ate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 1990;40:544-549
18. Costall B, Domeney AM, Kelly ME, et al. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35:607-615
19. Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 2008;196:417-429
20. Marston HM, Young JW, Martin FD, et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology 2009;206:699-714
21. Funke CW, Hindriks H, Sam AP. Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H- dibenz[2,3:6,7] oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 1990;40:536-539
22. Cosi C, Koek W. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol 2001;433:55-62
23. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73
24. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124:87-94
25. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
26. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharm 2009;23:65-73
27. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68:2269-2292
28. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-154
29. Schering-Plough. Saphris (Asenapine) sublingual tablets. Breifing document (Background Package). Schering-Plough Research Institute 2009
30. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78
31. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharm Biol Psychiatry 2003;27:1071-1079
32. Moore NA, Leander JD, Benvenga MJ, et al. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997;58(Suppl 10):37-44
33. Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 2009;602:334-342
34. Swerdlow NR, Weber M, Qu Y, et al. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008;199:331-388
35. Barch DM, Carter CS, Arnsten A, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 2009;35:109-114
36. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19
37. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-213
38. Nuechterlein KH, Luck SJ, Lustig C, Sarter M. CNTRICS final task selection: control of attention. Schizophr Bull 2009;35:182-196
39. Young JW, Powell SB, Risbrough V, et al. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009;122:150-202
40. Potkin S, Fleming K, Binnerman B, et al. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Eur Neuropsychopharm 2007;17:S466-7
41. Jentsch JD, Shahid M, Wong EHF, Roth RH. Asenapine improves cognitve function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine. Biol Psychiatry 2006;59(Suppl):471
42. Neill JC, Shahid M, Grayson B, et al. Asenapine improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat. Biol Psychiatry 2008;63(Suppl):75-76
43. Neill JC, Shahid M, Wong EHF, Idris NF. Comparison of the efficacy of asenapine, risperidone, and olanzapine to improve a reversal learning deficit in the rat. Schizophr Res 2006;81(Suppl):105-106
44. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
45. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-309
46. Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry 2009;43:277-282
47. Schering-Plough. Full Prescribing Information: Saphris (asenapine). 2009
48. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-1500
49. Curtis VA, Katsafouros K, Moller HJ, et al. Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharm 2008;22:254-261
50. Lane HY, Liu CC, Chang WH. Risperidone for exclusively negative symptoms. Am J Psychiatry 1999;156:335
51. Riedel M, Spellmann I, Strassnig M, et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007;257:360-370
52. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-115
53. Useful for corroborating the efficacy of asenapine for treating the positive symptoms for schizophrenia compared with a typical antipsychotic.
54. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009;86:84-91
55. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004;174:17-24
56. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49:1297-1308
57. Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010;43:138-146
58. Useful for corroborating the efficacy of asenapine for treating the positive symptoms for schizophrenia.
59. Weber J, McCormack PL. Asenapine. CNS Drugs 2009;23:781-792
60. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005;27:289-304
61. Choi YK, Wong EH, Henry B, et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-410
62. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-420
63. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv 2008;59:1207-1210
64. Tait DS, Marston HM, Shahid M, Brown VJ. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology 2009;202:295-306
65. Ornstein TJ, Sahakian BJ, McKenna PJ. Memory and executive impairment in schizophrenia: comparison with frontal and temporal brain damage. Psychiatry Med 2008;38:833-842
66. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-686